Wells Fargo & Company Forecasts Strong Price Appreciation for Glaukos (NYSE:GKOS) Stock

Glaukos (NYSE:GKOS) had its price objective hoisted by equities researchers at Wells Fargo & Company from $178.00 to $226.00 in a research report issued on Thursday, Benzinga reports. The brokerage currently has an “overweight” rating on the medical instruments supplier’s stock. Wells Fargo & Company‘s price target suggests a potential downside of 1.14% from the company’s previous close.

Other research analysts have also issued research reports about the stock. Wall Street Zen raised shares of Glaukos from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. Needham & Company LLC boosted their price target on shares of Glaukos from $201.00 to $251.00 and gave the stock a “buy” rating in a research note on Thursday. BTIG Research boosted their price target on shares of Glaukos from $205.00 to $234.00 and gave the stock a “buy” rating in a research note on Thursday. Jefferies Financial Group increased their price objective on shares of Glaukos from $190.00 to $210.00 and gave the company a “buy” rating in a report on Tuesday, September 22nd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Glaukos in a research note on Thursday, October 15th. Thirteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $201.57.

Glaukos Trading Up 26.0%

Shares of NYSE GKOS traded up $47.18 during midday trading on Thursday, hitting $228.61. The stock had a trading volume of 1,241,936 shares, compared to its average volume of 876,878. The firm has a market cap of $13.48 billion, a P/E ratio of -70.02 and a beta of 0.69. Glaukos has a fifty-two week low of $80.90 and a fifty-two week high of $229.27. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.04 and a quick ratio of 4.46. The company’s 50-day simple moving average is $171.24 and its 200 day simple moving average is $139.87.

Glaukos (NYSE:GKOS) last posted its quarterly earnings results on Wednesday, October 28th. The medical instruments supplier reported $0.47 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.57. The business had revenue of $211.03 million for the quarter, compared to analysts’ expectations of $168.04 million. Glaukos had a negative return on equity of 6.37% and a negative net margin of 30.68%. The firm’s quarterly revenue was up 58.0% compared to the same quarter last year. During the same quarter last year, the business earned ($0.16) earnings per share. Research analysts anticipate that Glaukos will post -0.32 EPS for the current year.

Insider Buying and Selling

In other news, COO Joseph Gilliam sold 60,000 shares of the company’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $179.74, for a total value of $10,784,400.00. Following the completion of the sale, the chief operating officer directly owned 72,588 shares of the company’s stock, valued at $13,046,967.12. This represents a 45.25% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Alex R. Thurman sold 20,000 shares of the stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $180.13, for a total transaction of $3,602,600.00. Following the completion of the sale, the chief financial officer owned 43,906 shares in the company, valued at $7,908,787.78. This represents a 31.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 83,025 shares of company stock worth $14,950,006 in the last ninety days. 5.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of GKOS. Allworth Financial LP bought a new stake in shares of Glaukos during the second quarter worth $28,000. CoreCap Advisors LLC bought a new stake in Glaukos in the 3rd quarter valued at $33,000. Fortitude Family Office LLC bought a new stake in Glaukos in the 3rd quarter valued at $36,000. IFP Advisors Inc lifted its position in Glaukos by 523.4% in the 2nd quarter. IFP Advisors Inc now owns 293 shares of the medical instruments supplier’s stock valued at $41,000 after acquiring an additional 246 shares in the last quarter. Finally, Parallel Advisors LLC boosted its stake in Glaukos by 159.2% in the 1st quarter. Parallel Advisors LLC now owns 368 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 226 shares during the period. Institutional investors own 99.04% of the company’s stock.

More Glaukos News

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Record growth and profitability: Third-quarter revenue rose 58% year over year to approximately $211 million, well above the $168 million analyst consensus. Glaukos reported adjusted EPS of $0.47 versus expectations for a $0.10 loss, while GAAP results showed $2 million in net income, or $0.03 per diluted share, compared with a loss in the prior-year quarter. Glaukos Q3 earnings and revenue report
• Positive Sentiment: Higher sales outlook: Management raised 2026 revenue guidance to $775 million-$785 million from $680 million-$700 million and introduced a preliminary 2027 sales target of approximately $1 billion. The outlook reflects continued momentum in the company’s glaucoma and corneal-health franchises, including iDose TR and Epioxa. Glaukos strong Q3 results and higher sales outlook
• Positive Sentiment: Analysts raised targets and ratings: Needham lifted its target to $251, BTIG raised its target to $234, and Stifel increased its target to $225; all three firms now rate GKOS “Buy.” The new targets imply meaningful upside from the stock’s recent trading level. Needham analyst ratings
• Positive Sentiment: Healthy financial position: Glaukos generated $14.8 million in operating cash flow and ended the quarter with $162.3 million in cash, supporting continued investment in product development and commercialization.
• Neutral Sentiment: The earnings call and financial releases will be closely watched for additional details on adoption, reimbursement, and the pace at which iDose TR and Epioxa can support the ambitious 2027 sales target. Glaukos Q3 earnings call transcript
• Negative Sentiment: Quiver data shows 32 open-market insider sales and no purchases over the past six months, including selling by senior executives. While such transactions may reflect compensation or diversification, the pattern is a potential secondary concern for investors.

Glaukos Company Profile

Glaukos Corporation is an ophthalmic medical-technology company focused on developing and commercializing therapies for chronic eye diseases. The company’s principal areas of focus include glaucoma, corneal disorders and retinal diseases, with an emphasis on treatments that may reduce reliance on conventional pharmaceuticals or more invasive surgical procedures.

Glaukos is best known for its micro-invasive glaucoma surgery (MIGS) products, including the iStent family of implantable devices used to help lower intraocular pressure in patients with glaucoma.